Alnylam Pharmaceuticals, Inc.
Coronavirus iRNA compositions and methods of use thereof
Last updated:
Abstract:
The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject.
Status:
Grant
Type:
Utility
Filling date:
17 May 2021
Issue date:
28 Dec 2021